These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3018894)

  • 1. Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay.
    Lewis RB; Matzke DS; Albrecht TB; Pollard RB
    Rev Infect Dis; 1986; 8 Suppl 4():S434-8. PubMed ID: 3018894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of immunoglobulin G preparations for anti-cytomegalovirus antibodies with reference to neutralizing antibody in the presence of complement.
    Eizuru Y; Ueno I; Minamishima Y
    J Clin Microbiol; 1988 Sep; 26(9):1881-3. PubMed ID: 2846652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus.
    Yajima M; Shiraki A; Daikoku T; Oyama Y; Yoshida Y; Shiraki K
    J Infect Chemother; 2015 Jun; 21(6):427-33. PubMed ID: 25824903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations.
    Planitzer CB; Saemann MD; Gajek H; Farcet MR; Kreil TR
    Transplantation; 2011 Aug; 92(3):267-70. PubMed ID: 21659947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cytomegalovirus (CMV)-specific neutralization capacity of hyperimmunoglobulin (HIG) versus standard intravenous immunoglobulin (IVIG) preparations: Impact of CMV IgG normalization.
    Schampera MS; Schweinzer K; Abele H; Kagan KO; Klein R; Rettig I; Jahn G; Hamprecht K
    J Clin Virol; 2017 May; 90():40-45. PubMed ID: 28342316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plaque reduction neutralization test for human cytomegalovirus based upon enhanced uptake of neutral red by virus-infected cells.
    Schmidt NJ; Dennis J; Lennette EH
    J Clin Microbiol; 1976 Jul; 4(1):61-6. PubMed ID: 182716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization and sensitization of cytomegalovirus by IgG antibody, anti-IgG antibody, and complement.
    Rundell BB; Betts RF
    J Med Virol; 1982; 10(2):109-18. PubMed ID: 6292359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid quantitation of cytomegalovirus and assay of neutralizing antibody by using monoclonal antibody to the major immediate-early viral protein.
    Chou SW; Scott KM
    J Clin Microbiol; 1988 Mar; 26(3):504-7. PubMed ID: 2833529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities.
    Gupta CK; Leszczynski J; Gupta RK; Siber GR
    Biologicals; 1996 Jun; 24(2):117-24. PubMed ID: 8889058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of sendai virus by the IgG subclass antibodies of the guinea pig.
    Togashi H; Tozawa H
    Microbiol Immunol; 1982; 26(9):821-9. PubMed ID: 6296641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of IgG subclasses to human cytomegalovirus.
    Gilljam G; Wahren B
    J Virol Methods; 1989 Aug; 25(2):139-51. PubMed ID: 2550502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of cytomegalovirus virions: the role of complement.
    Spiller OB; Hanna SM; Devine DV; Tufaro F
    J Infect Dis; 1997 Aug; 176(2):339-47. PubMed ID: 9237698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins.
    Miescher SM; Huber TM; Kühne M; Lieby P; Snydman DR; Vensak JL; Berger M
    Vox Sang; 2015 Jul; 109(1):71-8. PubMed ID: 25766313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of CMV ELISA antibody: titer and neutralizing activity in intramuscular immune globulin of placental origin.
    Gibert R; el Habib R; Allard JP; Defayolle M; Aymard M
    Transplant Proc; 1987 Oct; 19(5):4083-6. PubMed ID: 2823436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An enzyme immunoassay based micro-neutralization test for titration of antibodies to human cytomegalovirus (CMV) and its correlation with direct ELISA measuring CMV IgG antibodies.
    Gupta CK; Leszczynski J; Gupta RK; Siber GR
    Biologicals; 1996 Mar; 24(1):41-9. PubMed ID: 8733600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal IgM antibodies from cytomegalovirus-infected mice recognize the GlcNAc-containing receptor determinant of murine CMV as well as neutralizing anti-CMV IgG antibodies.
    Ravindranath RM; Graves MC
    Virology; 1992 May; 188(1):143-51. PubMed ID: 1373551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Properties of Human Cytomegalovirus Hyperimmunoglobulin and Standard Immunoglobulin Preparations.
    Germer M; Herbener P; Schüttrumpf J
    Ann Transplant; 2016 Sep; 21():558-64. PubMed ID: 27595792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of cytomegalovirus immune complexes with host cells.
    Rundell BB; Betts RF
    Infect Immun; 1981 Sep; 33(3):658-65. PubMed ID: 6269997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region.
    Furebring C; Speckner A; Mach M; Sandlie I; Norderhaug L; Borrebaeck CA; Turesson H; Ohlin M
    Mol Immunol; 2002 Mar; 38(11):833-40. PubMed ID: 11922941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical properties of cytomegalorvirus immune complexes prepared with IgG neutralizing antibody, anti-IgG, and complement.
    Rundell BB; Betts RF
    J Immunol; 1980 Jan; 124(1):337-42. PubMed ID: 6243148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.